Ann: Change in substantial holding, page-30

Nowhere have I offered a personal opinion on the efficacy, except to quote the facts regarding NZ and Canada and the scope of their approval and the ensuing marketing difficulties - if what I have said is factually wrong then that is why I come here to test my views. I don't know why different countries came up with different outcomes. I do agree that the Japanese have gone on the front foot with this technology and that will be a fascinating process to watch as it unfolds. My only comment in relation to MSB and Japan is the observation that JCR has the rights to prochymal in Japan and have been pushing it to market since 2003. The financials are unclear and rightfully so but they would buck the trend of every other pharma if, after 13 years of effort, they have not maximized their own gains in this area as much as possible.